Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)

NCT06775041 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Hutchinson-Gilford Progeria Syndrome

Interventions

DRUG: Progerinin
DRUG: Lonafarnib

Sponsor

PRG Science & Technology Co., Ltd.